Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
Creelan B, Gettinger S, Chesney J, Sukari A, He K, Lee S, Garon E, Nieva J, Martin-Liberal J, Rodriguez Moreno J, Zugazagoitia J, Doger de Spéville B, Josephs D, Gibney G, Thomas S, Samhouri Y, Samakoglu S, Feng M, Finckenstein F, Schoenfeld A. Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8659.Peer-Reviewed Original ResearchMetastatic non-small cell lung cancerNon-small cell lung cancerTumor-infiltrating lymphocytesCell lung cancerStandard-of-careIL-2Advanced non-small cell lung cancerLung cancerIn vivo T-cell persistencePhase 2 open-label studyECOG performance status 0Treatment-emergent adverse eventsResponse rateFrontline maintenance therapySymptomatic brain metastasesComplete response rateDisease control rateDose of pembrolizumabPerformance status 0Platinum-doublet chemotherapyT cell persistenceCell transfer therapyCirculating tumor DNAEGFR wild-typeEffective targeted therapies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply